Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
Although valganciclovir is an effective CMV prophylactic agent after kidney transplantation, it is associated with significant side effects.
Persisting evidence of cardio-renal involvement, hemostasis pathway activation reported at 28 to 60 days after discharge
In a study, aviremic recipients of HCV-positive and HCV-negative deceased donor kidneys had similar 12-month transplant outcomes.
Among donor selection criteria, COVID-19-positive deceased donors could not have significant primary or secondary kidney injury.
COVID-19-associated cystitis appears to be a common problem among infected individuals.
A study of 3090 patients with HIV seen at a tertiary care hospital from June 2019 to June 2020 revealed a 1.8% prevalence of advanced chronic kidney disease, an approximately 4-fold increase from 2008-2010.
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
Although extraction within 6 days is linked to lower mortality, hardware not removed in 78.9% of patients with infected devices.
Although peak oxygen increases after kidney transplantation, it remains lower than in age- and gender-matched healthy patients.